{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T01:27:01Z","timestamp":1782523621598,"version":"3.54.5"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,14]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Secukinumab, an IL-17A inhibitor, is approved for moderate to severe psoriasis in children over 6 years old in the European Union and the United States, but not yet in China. This study evaluates the clinical efficacy and safety of secukinumab in Chinese pediatric patients with moderate to severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A randomized, single-center study was conducted with 33 patients aged 6 to 17 years. Patients were treated with either secukinumab or conventional non-biologic therapy. The primary outcomes assessed included body surface area (BSA), Psoriasis Area and Severity Index (PASI) 75\/90\/100 responses, Investigator\u2019s Global Assessment 0\/1 (IGA 0\/1), Dermatology Life Quality Index, and the incidence of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Compared to the conventional treatment group, the secukinumab group demonstrated significant reductions in BSA and PASI scores, as well as higher rates of IGA 0\/1, Dermatology Life Quality Index improvement, and PASI 90 response. Subgroup analysis of the secukinumab group indicated lower BSA and PASI scores in patients without prior treatment compared to those with prior treatment. No significant differences were observed between the 150\u2009mg and 300\u2009mg dose groups regarding BSA and PASI decrease rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Secukinumab demonstrates therapeutic efficacy and safety in the treatment of moderate to severe plaque psoriasis in pediatric and adolescent patients, suggesting its potential as a treatment option for this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046058","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T21:00:47Z","timestamp":1763154047000},"page":"e46058","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of secukinumab in pediatric patients with moderate to severe plaque psoriasis: A randomized study"],"prefix":"10.1097","volume":"104","author":[{"given":"Yuping","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of dermatology, Zhongshan City People\u2019s Hospital, Zhongshan, China"},{"name":"National Clinical Research Center for Skin and Immune Disease, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiji","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of gastroenterology, Zhongshan City People\u2019s Hospital, Zhongshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of dermatology, Zhongshan City People\u2019s Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of dermatology, Zhongshan City People\u2019s Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of dermatology, Zhongshan City People\u2019s Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of dermatology, Zhongshan City People\u2019s Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0645-9776","authenticated-orcid":false,"given":"Chen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of dermatology, Zhongshan City People\u2019s Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251121","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis.","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"R2-20251121","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence.","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R3-20251121","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jid.2021.02.764","article-title":"New frontiers in psoriatic disease research, part I: genetics, environmental triggers, immunology, pathophysiology, and precision medicine.","volume":"141","author":"Yan","year":"2021","journal-title":"J Invest Dermatol"},{"key":"R4-20251121","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","article-title":"Epidemiology and comorbidity of psoriasis in children.","volume":"162","author":"Augustin","year":"2010","journal-title":"Br J Dermatol"},{"key":"R5-20251121","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2009.07.029","article-title":"Incidence of psoriasis in children: a population-based study.","volume":"62","author":"Tollefson","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R6-20251121","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R7-20251121","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/PPA.S350753","article-title":"Secukinumab for the treatment of psoriasis in pediatrics: patient selection and acceptability.","volume":"17","author":"Narbutt","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"R8-20251121","doi-asserted-by":"crossref","first-page":"528","DOI":"10.5694\/mja2.50591","article-title":"Beyond skin deep: addressing comorbidities in psoriasis.","volume":"212","author":"Kovitwanichkanont","year":"2020","journal-title":"Med J Aust"},{"key":"R9-20251121","first-page":"856","article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents - short version part 1.","volume":"17","author":"Eisert","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"R10-20251121","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis.","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"R11-20251121","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40272-022-00507-0","article-title":"Efficacy of secukinumab across subgroups and overall safety in pediatric patients with moderate to severe plaque psoriasis: week 52 results from a Phase III randomized study.","volume":"24","author":"Magnolo","year":"2022","journal-title":"Paediatr Drugs"},{"key":"R12-20251121","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaad.2021.08.066","article-title":"A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.","volume":"86","author":"Magnolo","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R13-20251121","doi-asserted-by":"crossref","first-page":"e15456","DOI":"10.1111\/dth.15456","article-title":"Successful treatment of nevoid psoriasis with Secukinumab in a pediatric patient.","volume":"35","author":"Neema","year":"2022","journal-title":"Dermatol Ther"},{"key":"R14-20251121","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1080\/09546634.2021.1899111","article-title":"Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series.","volume":"33","author":"Albela","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R15-20251121","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamadermatol.2019.4835","article-title":"A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents.","volume":"156","author":"Bronckers","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R16-20251121","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update.","volume":"183","author":"Smith","year":"2020","journal-title":"Br J Dermatol"},{"key":"R17-20251121","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R18-20251121","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/exd.14784","article-title":"Infantile generalized pustular psoriasis with excellent response to secukinumab: a case report.","volume":"32","author":"Guevara","year":"2023","journal-title":"Exp Dermatol"},{"key":"R19-20251121","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jdv.17002","article-title":"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial.","volume":"35","author":"Bodemer","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R20-20251121","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.","volume":"73","author":"Thaci","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R21-20251121","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/1346-8138.16551","article-title":"Real-world data on the use of secukinumab and acitretin in pediatric generalized pustular psoriasis.","volume":"50","author":"Miao","year":"2023","journal-title":"J Dermatol"},{"key":"R22-20251121","doi-asserted-by":"crossref","first-page":"1009991","DOI":"10.3389\/fmed.2022.1009991","article-title":"Biologics for psoriasis patients under 18 years of age: real-world evidence from the Chinese psoriasis real world evidence research group.","volume":"9","author":"Zheng","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R23-20251121","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/pde.14737","article-title":"Rapid response to secukinumab in a 5-year-old with deficiency of the interleukin-36 receptor antagonist (DITRA) with severe scalp and nail involvement.","volume":"38","author":"Jing","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"R24-20251121","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/pde.14795","article-title":"Successful treatment of a 3-year-old girl with generalized pustular psoriasis using secukinumab monotherapy.","volume":"38","author":"Zhu","year":"2021","journal-title":"Pediatr Dermatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:00:56Z","timestamp":1763766056000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":24,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046058","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"2024-07-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}